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patients (23%) who received RIC regimen.
Median OS for patients who received HCT was 551 days
while it was 200 days for patients who did not receive HCT
(p¼0.0013) Fig1. The median OS for patients who got RIC was
1095 days but less at 434 days for MA patients but not sta-
tistically signiﬁcant (p¼0.64) Fig2. The cumulative incidence
of relapse was not different between the two groups.
Conclusion: In this small cohort of consecutive patients from
a single center, the results suggest that HCTcan be performed
in patients with high and Intermediate-risk AML patients
including older patients using RIC. RIC in older patients and
MA in younger patients did not differ in term of OS. However
this is limited by the small number of patients and a larger
prospective evaluation is needed taking into consideration
better models encompassing performance status and co-
morbidities.Fig 2.339
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Background: Myelodysplastic syndromes (MDS) are a het-
erogeneous group of malignancies characterized by
dysplasia, cytopenia, ineffective hematopoiesis and by an
increased risk of transformation to acute myeloid leukemia
(AML). Recurrent aberrant karyotypes cannot entirely ac-
count for the genetic defects that are at the basis of the
pathogenesis of MDS, as they are detected only in approxi-
mately 50% of patients.
Allogeneic hematopoietic cell transplantation (HCT) likely
prolongs survival in patients with AML and MDS. In this
report, we evaluated the impact of presence of dyspoesis in
paients with AML with or without cytogenetic (CG) abnor-
mality on outcome in our center.
Methods: We retrospectively reviewed all patients who
were diagnosed with AML (non promyelocytic) in our center
between 2002 and 2012. Primary objective was to study the
impact ofMDSwith or without CG abnormalities on outcomeof patients with AML. Demographics and disease-related
variables were collected. OS was deﬁned as the time from
diagnosis to the time of death or last contact.
Results: Between 2002 and 2012, 123 patients with high or
intermediate risk AML patients were treated at our center.
Median age at diagnosis was 60 (range 19-89). Median OS for
all patients was 368 days. Of 123 patients, 51 had MDS while
73 did not. CG abnormalities were present in 35 (68%) of
patients with dyspoetic changes. Median age of AML patients
with MDS was 59 while median age of AML without MDS
patients was 55. Median number of blasts in bone marrow
and peripheral blood in AML patients with MDSwas 38% and
6% respectively. While median number of blasts in bone
marrow and peripheral blood in AML patients without MDS
was 67% and 39% respectively. Of 51 AML patients with MDS,
14 received HCTwithmedian age of 56. Half of these received
myeloablative regimenwhile the other half received reduced
toxicity regimen.
The median survival time for AML patients without MDS
was 401 days while the median survival time for AML pa-
tients with MDS was 278 days (p ¼ 0.0201), Fig1.
For AML with MDS who received HCT, the median sur-
vival time was 586 days while it was 164.5 days for AML
patient withMDSwho did not receive HCT (p¼ 0.0013), Fig2.
Conclusion: In this small cohort from a single center, the
results suggest that AML patients with dyspoetic changes do
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S221have a worse prognosis despite having lower percentage of
blasts in bone marrow or peripheral blood. This can be
explained by what Walter et al reprted, using next-genera-
tion sequencing, that the proportion of neoplastic marrow
cells is indistinguishable in MDS and secondary-AML even
with myeloblast count of zero. HCT can be performed in
those patients including older patients with promising
results.340
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Background: Busulfan crosses the blood-brain barrier and at
high doses can cause severe neurotoxicity, including seizures
that are most commonly tonic-clonic in character. When
Busulfan is used in the conditioning of patients undergoing
hematopoietic cell transplantation (HSCT), phenytoin, ben-
zodiazepines, or newer anticonvulsants such as levetir-
acetam are often used for seizure prophylaxis. Phenytoin is a
potent inducer of cytochrome P450 hepatic enzymes that
leads to higher clearance of Busulfan. Phenytoin is also
capable of altering cyclophosphamide levels by affecting its
metabolism and formation of hydroxy-cyclophosphamide
through uridine glucoronosyltransferase enzymes and may
also affect HSCT outcomes such as increased risk of sinusoi-
dal obstructive syndrome (SOS). In this report, we evaluated
the impact of levetiracetam versus phenytoin on effective-
ness of seizure prophylaxis and development of SOS in our
center.
Methods: We retrospectively reviewed Allogeneic HSCT
patients who received intravenous Busulfan for 4 days as part
of their conditioning regimen in our center between 2002
and 2013. Primary objective was to study the impact of
phenytoin and levetiracetam on effectiveness of seizure
prophylaxis and SOS. Demographics and disease-related
variables were collected.
Results: Between 2002 and 2013, 106 patients received
Busulfan intravenously once daily for 4 days as part of part of
their conditioning regimen for allogeneic HSCT. Median age
at diagnosis was 56 (range 19-73). Median OS for all patients
was 316 days. Of these 106 patients, seventy-seven patients
(73%) received a regimen that included both Busulfan and
Cyclophosphamide (BUCY),while twenty-nine patients (27%)
received a regimen that included both Busulfan and Fludar-
abine (FluBu).Median age of patientswho received BUCYwas
54 while median age of patients who received FluBu was 60.
Sixty-four (60%) patients received phenytoin while 42 (40%)
received levetiracetam. Of 106, none developed seizures.
Only two patients developed SOS; one who received BUCY
and got phenytoin as seizure prophylaxis and the other one
received FluBu and got levetiracetam as seizure prophylaxis.
Both patients were on Low molecular weight heparin.
Conclusion: In this small cohort from a single center where
Busulfan Kinetics is not monitored, there is low incidence of
SOSwhether using BUCYor FluBu as conditioning regimen and
without anydifference betweenphenytoin or levetiracetamon
effectiveness of seizure prevention or SOS incidence.341
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HCT is the only known curative treatment for MDS. Treat-
ment with the DNA methyltransferase inhibitor azacitidine
(aza) has been utilized prior to HCT for tumor debulking and
to slow leukemic progression. To discern the impact of aza
treatment, we retrospectively analyzed the post transplant
outcomes of 159 patients (pts) according to pre-HCT aza
exposure. Patients included those with a diagnosis of MDS or
CMML at any time point in their disease course and subse-
quently received a HCT. Eligible patients proceeded to HCT if
they had adverse disease features such as elevated IPSS risk,
treatment related MDS, progression or refractory disease.
Consecutive patients receiving a HCT from July 2004 and
May 2011 were evaluated. All obtained a myeloablative HCT
using ﬂudarabine and IV-busulfan [targeted to an AUC of
3500, 5300, 6000 or 7500]. GVHD prophylaxis was with
tacrolimus plus either methotrexate or sirolimus or myco-
phenolate mofetil. Those with mismatched donors also
received ATG.
Seventy pts, median age of 56.5 (24.8 e 71.6) years (yrs), did
not receive pre-transplant aza (NOAZA group). Forty ptswere
older than 55 yrs (57%). At diagnosis, IPSS risk was Low (4),
Int-1 (25), Int-2 (17), High (5), not evaluable (4) (NE), AML (6)
and CMML (9). Twenty-one had treatment related MDS and
15 had AML at one time. Donors included 28 match related
donors (MRD), 31 matched unrelated donors (MUD) and 11
mismatched unrelated donors (mMUD). Median follow-up of
surviving patients was 70.0 (29.7 e 106.6) months.
Eighty-nine pts, median age of 57.8 (25.6 e 73.8) yrs,
received a median of 4 (1-12) cycles of aza prior to HCT (YES
AZA group). Fifty-four (61 %) were older than 55 yrs. At
diagnosis, IPSS risk was Low (n¼4), Int-1 (n¼26), Int-2
(n¼32), High (n¼15), NE (n¼2), AML (n¼2) and CMML (n¼8).
Twenty-three had treatment related MDS and 11 had AML at
one point. Donors included MRD (n¼38), MUD (n¼40) and
mMUD (n¼11). Median follow-up of surviving patients was
48.3 (24.1 e 103.2) months.
Prior to allografting the number of marrow blasts in the No-
AZA vs Yes-AZA was: <5% (n¼41 vs 49), 5-10% (n¼12 vs 19),
11 e 20% (n¼10 vs 11), >20% (n¼3 vs 4) and CMML (n¼4 vs
6). All patients engrafted with no difference in engraftment
rates or toxicities between the groups. At 3 years, the RFS and
OS suggest improvement with preHCT AZA and approached
statistical signiﬁcance.
